Plasminogen Activator Inhibitor Type-1 (PAI-1) Levels Are Decreased in NIDDM Patients treated with Insulin

Abstract

We examined 25 non-insulin-dependent diabetes mellitus (NIDDM) patients treated with sulfonylurea (SU) regi mens, 14 NIDDM patients with 8-12 weeks long-acting insulin (INS) treatment and 15 age-matched normoinsulinemic healthy controls. Plasminogen activator inhibitor-1 (PAI-1) levels were significantly increased in NIDDM patients treated by SU agents (median 58.9, range 14-217 ng/ml) compared to patients with insulin therapy (median 20.7, 4-53 ng/ml) and normal controls (median 10.8, 4-52 ng/ml) (p < 0.001). Non-insulin- dependent diabetes mellitus subgroups were not different in other hemostatic (von Willebrand factor, thrombomodulin, tis sue factor pathway inhibitor, platelet factor-4 levels) and meta bolic (C-peptide, triglycerides) parameters and PAI-1 levels did not correlate with these hemostatic and metabolic parameters. This finding suggests that insulin application itself may cause decreased PAI-1 levels, probably by influence on intracellular calcium. This hypothesis requires further research. Key Words: PAI-1—Insulin treatment—Non—insulin—dependent diabetes mellitus.

Get full access to this article

View all access options for this article.

References

Alessi MC , Juhan-Vague I. , Kooistra T. , et al. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by hepatocellular cell line HepG2. Thromb Haemost 1988;60:491.

Hamsten A. , Eriksson P. Fibrinolysis and atherosclerosis: an update. Fibrinolysis 1994;8:253.

Juhan-Vague I. , Alessi MC , Vague P. Increased plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis . Diabetologia 1991;34:457.

Vague P. , Juhan-Vague I. , Aillaud MF , et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986 ;35:250.

Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995;74:71.

Jokl R. , Lazarchick J. , Johnston PS , Colmell JA Postprandial activation of fibrinolysis with type 2 diabetes mellitus . Abstracts of 15th International Diabetes Federation Congres. Kobe, 1994:301.

Mehrabian M. , Peter JB , Barnard RJ , et al. Dietary regulation of fibrinolytic factors. Atherosclerosis 1990 ;84:25.

Marckmann P. Diet, blood coagulation and fibrinolysis. Dan Med Bull 1995;42:410.

Kubo K. , Takashina S. Relationship between plasma insulin and plasminogen activator inhibitor-1 in non insulin dependent diabetic patients. Abstracts of 15th International Diabetes Federation Congres. Kobe , 1994:380.

10.

Lindstrom T. , Olsson AG , Vonschenck H. , et al. Insulin treatment improves microalbuminuria and other cardiovascular risk factors in patients with type 2 diabetes mellitus . J Int Med 1994;235:253.